Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solid Tumor 1Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × ARRY-334543 × Clear all
NCT03130790 2022-02-15

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

ASLAN Pharmaceuticals

Phase 2/3 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03093870 2021-08-03

TreeTopp

ASLAN Pharmaceuticals

Phase 2/3 Completed
151 enrolled 18 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed
31 enrolled
Other solid neoplasm

Solid Tumor

NCT02609958 2018-05-29

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

ASLAN Pharmaceuticals

Phase 2 Completed
32 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡